Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

• Status: Completed
• Trial end date: 2007-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Enzastaurin given daily to patients with non-small cell lung cancer who have failed at least one prior therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Must be at least 18 years old

• Must have been diagnosed with advanced or metastatic non-small cell lung cancer

• Must be able to visit the doctor's office every 28 days for 6 months or longer.

Exclusion Criteria:

• Pregnant or breastfeeding women

• Have other significant medical problems as determined by your physician

• Are unable to swallow tablets

• Have a history of significant heart disease